Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report

Fan, Birao; Wang, Mingyue

doi:10.2340/actadv.v102.1378

Cited by 5 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies report high efficacy and survival rates with ruxolitinib for treating SR-GVHD. Based on the similarities in pathogenesis and clinical features of PNP and GVHD, ruxolitinib was considered a potential option for managing persistent stomatitis and BO in a female PNP patient ( 60 ) ( Table 4 ). Despite the patient experiencing consistent healing of the skin with prednisolone, azithromycin, and cyclosporine, there was no noticeable improvement in oral lesions and respiratory function until ruxolitinib was added.…”

Section: Application Of Jak Inhibitors In Aibdsmentioning

confidence: 99%

Janus kinase inhibitors in autoimmune bullous diseases

et al. 2023

View full text Add to dashboard Cite

Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for AIBD involves the use of glucocorticoids or traditional immunosuppressants. Additionally, the utilization of biological agents such as rituximab, omalizumab, and dupilumab is on the rise. However, effectively managing AIBD remains a challenge. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway has been implicated in various inflammatory diseases. In recent years, a range of drugs known as JAK inhibitors, which target this pathway, have been developed. Several studies have explored the efficacy and safety of JAK inhibitors for treating AIBD. Consequently, this review begins by examining the role of the JAK/STAT pathway in AIBD, summarizing the application of different JAK inhibitors in AIBD treatment, and emphasizing the importance of disease management in treating AIBD with JAK inhibitors. Furthermore, it highlights the need for a better understanding of the JAK/STAT pathway’s role in AIBD, as well as the effectiveness and safety of JAK inhibitors for treating this disease.

show abstract

Section: Application Of Jak Inhibitors In Aibdsmentioning

confidence: 99%